Abstract
Whether likened to a “changeling demon” [1] or to the “troll of transplantation” [2], the human cytomegalovirus (HCMV) has long been known to exact a heavy toll on morbidity and mortality rates among newborn children and immunosuppressed individuals. A recent analysis by the Institute of Medicine of the National Academy of Sciences placed the development of a vaccine against HCMV in its highest category of priority: vaccines that would actually save money for society once they were applied [3]. The same conclusion was reached in a previous analysis [4].

This publication has 13 references indexed in Scilit: